Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - beclometasone dipropionate - inhalation powder - 200microgram

Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - beclometasone dipropionate - inhalation powder - 400microgram

Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

orion pharma (uk) ltd - beclometasone dipropionate - inhalation powder - 200microgram/1dose

Malasja - Ingliż - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

kotra pharma (m) sdn. bhd. - beclometasone dipropionate -

Malasja - Ingliż - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

kotra pharma (m) sdn. bhd. - beclometasone dipropionate -

Malta - Ingliż - Medicines Authority

chiesi farmaceutici s.p.a via palermo 26/a, 43122 parma, italy - beclometasone dipropionate, formoterol fumarate, dihydrate - pressurised inhalation, solution - beclometasone dipropionate 100 µg formoterol fumarate dihydrate 6 µg - drugs for obstructive airway diseases

Iżrael - Ingliż - Ministry of Health

kamada ltd, israel - beclometasone dipropionate; formoterol fumarate dihydrate; glycopyrronium as bromide - pressurised solution - glycopyrronium as bromide 9 mcg/delivered dose; formoterol fumarate dihydrate 5.2 mcg/delivered dose; beclometasone dipropionate 87.4 mcg/delivered dose - formoterol, glycopyrronium bromide and beclometasone - copd maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist. asthma maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.…

Iżrael - Ingliż - Ministry of Health

kamada ltd, israel - beclometasone dipropionate anhydrous; formoterol fumarate dihydrate - pressurised solution - formoterol fumarate dihydrate 6 mcg/actuation; beclometasone dipropionate anhydrous 200 mcg/actuation - formoterol and beclometasone - foster 200/6 is indicated in the regular treatment of asthma in adults where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2-agonist or- patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists.

Malta - Ingliż - Medicines Authority

glaxo wellcome uk limited - beclometasone dipropionate - nasal spray, suspension - beclometasone dipropionate 50 µg - nasal preparations

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - beclometasone dipropionate 1 mg/g equivalent to beclometasone dipropionate 100 mcg per spray - nasal spray solution - 100 mcg/dose - active: beclometasone dipropionate 1 mg/g equivalent to beclometasone dipropionate 100 mcg per spray excipient: benzalkonium chloride dispersible cellulose glucose hydrochloric acid phenethyl alcohol polysorbate 80 purified water - becloclear 100 is indicated in adults and children over six years of age for the prevention and treatment of seasonal and perennial allergic rhinitis and vasomotor rhinitis. becloclear 100 can significantly delay the recurrence of nasal polyps in those patients who have undergone nasal polypectomy. in those polyps that do recur, becloclear 100 can suppress their increase in size.